Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuprofen and EXCAP for Cognitive Function in Cancer Patients
NCT01238120Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Nov 2010
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ibuprofen in cancer-related cognitive impairment (CRCI) (4 arms), sponsored by University of Rochester. Primary endpoint: Memory Performance as Assessed by Computerized Cognitive Assessment at 6 weeks. Started Nov 2010; status: completed.
02
Drugs
ibuprofen
03
Conditions
cancer-related cognitive impairment (CRCI)
Beyond the preview
Go deeper on NCT01238120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01238120.